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Background: The aim of this study was to determine the risk for Bipolar Disorder (BD) in Wilson’s disease (WD) and
to measure the impaired Quality of Life (QL) in BD with WD using standardized psychiatric diagnostic tools and a
case control design.
Methods: This was a case control study. The cases were 23 consecutive patients with WD treated at the University
Hospital in Cagliari, Italy, and the controls were 92 sex- and age-matched subjects with no diagnosis of WD who
were randomly selected from a database used previously for an epidemiological study. Psychiatric diagnoses
according to DSM-IV criteria were determined by physicians using structured interview tools (ANTAS-SCID). QL was
measured by means of SF-12.
Results: Compared to controls, WD patients had lower scores on the SF-12 and higher lifetime prevalence of
DSM-IV major depressive disorders (OR = 5.7, 95% CI 2.4–17.3) and bipolar disorders (OR = 12.9, 95% CI 3.6–46.3). BD
was associated with lower SF-12 in WD patients.
Conclusions: This study was the first to show an association between BD and WD using standardized diagnostic
tools and a case control design. Reports in the literature about increased schizophrenia-like psychosis in WD and a
lack of association with bipolar disorders may thus have been based on a more inclusive diagnosis of schizophrenia
in the past. Our findings may explain the frequent reports of loss of emotional control, hyperactivity, loss of sexual
inhibition, and irritability in WD patients. This study was limited by a small sample size.Background
Wilson’s disease (WD) is an inherited autosomal reces-
sive disorder that affects copper metabolism. It is caused
by mutations in a gene on chromosome 13 that encodes
ATP 7B, an adenosine triphosphatase involved in copper
transportation across cell membranes [1,2]. The preva-
lence of WD is approximately 1:30,000, with a carrier
prevalence of 1:90 [3]. Prompt diagnosis and treatment
is critical; the disease is fatal unless treated, and effective
treatment is available [4]. The clinical manifestations of
WD result from gradual accumulation of free copper in
tissues, which can damage many organs. Most WD
patients have signs of liver and central nervous system
involvement. WD at presentation can have diverse clin-
ical features, including hepatic, neurological, and psychi-
atric manifestations. WD is usually diagnosed in patients
between 6 and 8 years of age when symptoms first be-
come clear [5]. Onset in patients >40 years is rare [6].* Correspondence: mgcarta@tiscali.it
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reproduction in any medium, provided the orThe psychiatric manifestations of WD have been
reported frequently since the original paper by S.A.K
Wilson was published in 1912 [7]. In his report, Wilson
describes psychiatric symptoms in 8 of 12 cases, and
“schizophrenia-like psychosis” in 2 of the cases. Other
reports describe a wide spectrum of psychiatric disor-
ders, including cognitive impairment [8], dementia [9],
mental retardation [10], anxiety [11], “schizophrenia-like
states” [12], and behavior abnormalities and personality
disorders [13].
Depression is extremely common in WD patients,
affecting 30–60% of those with WD [13,14]. An associ-
ation between the degree of disability and the presence
of depression has not been established, however. Fur-
thermore, the prevalence of depression is higher in WD
than in other chronic disabling diseases, such as rheum-
atic arthritis, even when there is a similar level of dis-
ability [15].
Other mood disorders, such as hypomania and frank
mania have also been reported in WD in recent years in
two large case series [16,17] and there is some evidencetd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in which a manic episode preceded the onset of neuro-
logical symptoms [18,19].
Costa-Machado and colleagues [18] suggested that
there may be a higher association between bipolar dis-
order and WD than has been reported in literature.
A study confirming the case series evidence with using
standardized diagnostic criteria and a matched case con-
trols methodology will be of interest in terms of clinical
practice, and probably in accordance with the broaden-
ing of the concept of bipolar disorder in present day
psychiatry [20]. Indeed, recent studies indicate that
higher levels of copper, similar to several other trace ele-
ments such as zinc, cadmium, and thallium, may play a
role in the pathophysiology of bipolar disorder, which is
consistent with the neurodegenerative hypothesis of
such a disorders [21].
The objectives of this study were to determine the fre-
quency of bipolar disorders and mood disorders in a
consecutive series of WD inpatients using standardized
diagnostic tools and to compare the risk for bipolar dis-
order in WD patients with the risk in controls. Data
were collected from the controls for use in a large epi-
demiological study [22,23].
The subjective perception of quality of life is a con-
struct that is very relevant to measures of outcomes in
chronic disease [24,25], particularly in patients with dis-
eases that impact heavily the daily life of the affected
patients and their families [26], such as WD. Thus, the
secondary objective of this study was to evaluate the im-
pairment of quality of life and the relationship between
mood disorders and impaired quality of life in WD.
Methods
Study design
This was a case control study.
Groups
The cases were 23 consecutive WD patients seen be-
tween January and September 2010 at the Gastroenter-
ology Unit at the University Hospital in Cagliari, Italy, a
center of excellence that cares WD patients from all
regions in Italy. The controls included 92 subjects with
no diagnosis of WD who were randomly selected from a
database used for an epidemiological study of health
conditions in Italy [22,23]. The selection of sex- age-and
residence matched controls from the 3498-subject data-
base from six Italian regions (2 from the North, 1 from
the Center, 2 from the South plus Sardinia) was per-
formed using a randomized block design. A block was
constructed for each case that included all eligible age-
matched (± 1 year),sex-matched and residence-matched
(North 1 Case 4.3%, South 1 Case 4.3%, Center 0% Italy
and Sardinia 21 Cases = 82.6%) controls in the database.Four individuals per block were extracted for each case,
automatically excluding them from remaining blocks.
Psychiatric diagnosis interview, tools, and psychiatric
assessment
The psychiatric interviews were conducted using several
standardized tools. First, we used a standard form to rec-
ord basic demographic data. Second, the “Advanced
Neuropsychiatric Tools and Assessment Schedule”
(ANTAS) [22], a semi-structured clinical interview
derived in part from the non-patient version (SCIDI/NP)
for DSM-IV [27] (First et al. 2001), was used to assess
the presence of full or sub-threshold psychiatric disor-
ders. The ANTAS tool was administered by physicians,
which was necessary for it to be administered according
to the study protocol. A preliminary reliability study of
the diagnoses derived from ANTAS and SCID was car-
ried out, and the results were published previously. The
reliability in terms of mood and anxiety diagnoses using
ANTAS vs. SCID was measured, and the mean K was
0.85 [20]. Third, the Mood Disorder Questionnaire
(MDQ; Italian version) [28] was used to assess bipolar
spectrum disorders. The adopted MDQ cut off was 7
(Bipolar Cases identified by score of 7 or more) [28].
Fourth, quality of life was evaluated with the Short
Form Health Survey (SF-12) [29]. The SF-12 includes
the following dimensions: physical activity, physical
health limitations on roles or activities, emotional state,
physical pain, self-evaluation of general state of health,
vitality, social activity, and mental health. The period of
measurement was the month prior to evaluation. Higher
scores on the SF-12 correspond to better conditions and
quality of life. Finally, the interviewers asked the inter-
viewees to show them the packages of drugs they used
and then retained all of the psychotropic drug box cov-
ers in a folder provided for this purpose.
Diagnosis of WD
The diagnosis for each WD patient was made by evaluat-
ing the clinical symptoms, laboratory test results, and
results of mutation analysis [30]. Confirmation of the clin-
ical diagnosis included decreased serum ceruloplasmin
concentration, high serum non-ceruloplasmin-bound cop-
per concentration, low serum copper concentration, ele-
vated 24-h urinary copper excretion, elevated hepatic
copper content (>250 μg/g dry weight), the presence of
Kayser-Fleischer rings by slit lamp examination, and
ATP7B mutation.
Liver function tests were performed, including alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), and g-glutamyl transpeptidase (GGT) tests.
Quantitative determination of serum ceruloplasmin con-
centrations was performed using automated clinical
chemistry analyzers (Array Protein System 360, Beckman
Table 1 Demographic Data and SPECT positivity in the
sample
Cases (23) Controls (92)
Age (mean± sd) 42.02 ± 12.52 42.35 ± 10.29
Age at diagnosis (media ± sd) 30.19 ± 18.28
sex
m 9 39.1% 36 (39.1)
f 14 60.9% 56 (60.9%)
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assay. The reference range for serum ceruloplasmin is
between 200–600 mg/liter. Serum copper and urinary
copper concentrations were measured using an induct-
ively coupled plasma optical emission spectrometer. The
reference range for serum copper is 10–22 μmol/liter. In
WD, the urinary copper output is >1.5 μmoles/24 h.
Liver copper concentration in dried liver tissue was mea-
sured by flame atomic absorption spectroscopy (Instru-
mentation Laboratory Video 22). Liver copper content
>250 μg/g dry weight is diagnostic for WD.
Screening controls for WD
During the interviews of the controls, each was asked
about general well being, the presence of illness, consult-
ation with physicians, and medical tests they underwent
both routinely (e.g., work or driver license eligibility
tests) or to help diagnose or monitor medical issues.
Diagnosis of physical illness was reported using a struc-
tured form.
Data analysis
Lifetime prevalence for DSM-IV major depressive dis-
order, bipolar disorder, panic disorder, and “at least a
diagnosis of anxiety by DSM-IV” was calculated for the
case and control groups, as was lifetime positivity (a score
>12) on the MDQ as an indicator of bipolar spectrum
disorder. The odds ratio association (univariate analysis)
for DSM-IV diagnosis (dependent variable) was calculated
using the control group as "pivot". Statistical significance
was calculated using the χ2 test in 2 × 2 tables. Odds ratio
95% confidence intervals (OR 95% CI) were calculatedTable 2 Lifetime Prevalence of Psychiatric Disorders and Qua
Cases Controls
(N= 23) (N= 92)
SF12 33.76 ± 9.0 38.14 ± 6.4
MDQ 9 (39.1%) 9 (9.8%)
Lifetime MDD 11 (47.8%) 11 (11.9%)
Bipolar Disorder 7 (30,4%) 3 (3.3%)
Panic Disorder 2 (8.7%) 5 (5,4%)
Total Anxiety Disorder 4 (17.3%) 6 (6.5%)using the method of Miettinen [31]. The comparisons be-
tween the scores at SF-12 in the study groups were calcu-
lated using the ANOVA one-way statistic, in alternative,
particularly when the size of the samples did not allow the
use of parametric test, the U Mann Whitney test was
used.
Ethics
Each study subject provided informed consent for the
use of anonymous data for an aggregate study. The com-
munity study (involving the controls) was approved by
the ethics committee of the Italian National Health Insti-
tute (Rome), and the present study was approved by the
ethics committee at the Università Europea del Mediter-
raneo ONLUS. Data were not nominal at the source,
and each subject was identified with a code number.
Results
The demographic characteristics of the study subjects
are shown in Table 1. Age and sex were homogeneous in
cases and controls due to the matching method. The
mean time on illness for WD patients was about 12 years.
Patients with WD had lower SF-12 scores than controls
(Table 2), a higher lifetime prevalence of manic/hypo-
manic episodes (with positivity as assessed on the
MDQ), and a higher prevalence of lifetime DSM-IV
major depressive disorders and bipolar disorders as
detected by the ANTAS interview. The differences be-
tween cases and controls in terms of the frequency of
panic disorders and total anxiety disorders were notable
but not statistically significant: 8.7% vs. 5.4% for panic
disorders, and 17.3% vs. 6.5% for all anxiety disorders in
cases and controls, respectively.
Table 3 compares Subjective Quality of Life (measured
as SF-12 score) in WD patients with Bipolar Disorders
(N= 7) – column left; and MDD (N=11) column right;
WD with Bipolar Disorder patients had SF-12 mean
score worse than WD patients without Bipolar Disorders
(N= 16, 11 of which had MDD) [F (1,21,22 df ) = 4.75,
P = 0.041 ANOVA 1 way]; had a worse mean SF-12 of
WD patients without MDD or Bipolar diagnosis (23WD
– 11 (MDD) – 7 (BD) = 5 cases) but the difference notlity of Life in Cases and Controls
Stat (DF) p OR Cl 95%
F(1,113,114) = 7.34 0.008
X2 = 4.88 (1) 0.002 5.9 1.3–27.1
χ2= 13.07 (1) 0.001 6.7 2.4–17.3
χ2= 13.86 (1) 0.001 12.9 3.6–46.3
χ2= 0.10 (1) 0.922 1.7 0.1–48.1
χ2= 1.54 (1) 0.215 4.5 0.41–48.4
Table 3 Quality of Life (SF-12 mean± standard deviation score) and Mood Disorders in Wilson’s Diseases Patients
Bipolar Disorders (N= 7) MDD (N=11)
SF12= 27.5 ± 7.1 SF-12= 34.4 ± 8.2
Non Bipolar (N = 16) F(1,21,22 df) = 4.75
SF-12 = 36.59.8 P = 0.041 —————————————————
Non MDD (N= 12) ——————————————— F(1,21,22) = 0.43
SF-12 = 32.1 ± 9.0 P = 0.519
Non MDD or BD (N = 5) U = 8, Z = -1,54, U = 24,Z = -0,40
SF-12 = 37.6 ± 7.6 P = 0.159 P = 0.74
Bipolar Disorders (N = 7) ————————————————— F(1,16,17) =3.31
SF12 = 27.5 ± 7.17.1 P = 0.087
MDD (N= 11) F(1,16,17) =3.31 ————————————————————————
SF-12 = 34.4 ± 8.2 P = 0.087
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P = 0.159, using Mann-Withney test due to the not ap-
plicability of parametric test]; had SF-12 mean score
worse than WD patients with MDD (N= 11), [F(1,16,17)
=3.31, P = 0.087, Anova 1 way]. WD with MDD patients
had SF-12 mean score higher than WD patients without
MDD (N=12, 7 of which had BD), but without any sta-
tistically significance [F(1,21,22) = 0.43, P = 0.519,
ANOVA 1 way]; had a worse mean SF-12 of WD
patients without MDD or Bipolar diagnosis (23WD – 11
(MDD) – 7 (BD) = 5 cases) but the difference not reach
the statistically significance [U= 24,Z = -0,40, P = 0.74,
using Mann-Withney test due to the not applicability of
parametric test];
Discussion
This study is the first to use a standardized epidemio-
logical case–control design and standardized diagnostic
tools (DSM-IV SCID-ANTAS) for studying the associ-
ation between mood disorders and WD. The results
indicated that the lifetime prevalence of DSM-IV bipolar
and major depressive disorders is higher in people with
WD than in sex- and age-matched controls. The OR
was 12.9 for bipolar disorders and 6.7 for major depres-
sive disorders. Notably, there was a difference in preva-
lence even though (due the random hazard method) the
randomized control sample had a particularly high
prevalence of bipolar and major depressive disorders
than the population from which it was drawn [22]. For
example, MDQ positivity was 3.0% in the database
population, but 9.8% in the random control sample.
These differences were in part due to the fact that MDQ
frequencies are highly influenced by sex, age and, in par-
ticular residency, and a high frequency in the control
group is likely because of these variables. While the con-
trols had a higher prevalence of MDQ (and BP detected
by SCID-ANTAS thus, with another method) than in
the population from which it was extracted, cases ofWD had higher prevalence of MDQ+ and BP-DSMIV at
statistically significant level than the controls.
According to the algorithm of DSM-IV MDD diagnosis
excludes BP and vice versa, and 11 (47.8%) cases had
MDD and 7 (30.4%) had BD. The percentage of cases with
depressive disorder is in the same range as previous stud-
ies cited in the introduction (30–60% for depression as
noted in the review of Akil and Brewer [13]). In general,
the previous case series showed about 60–80% of comor-
bidity between WD and psychiatric disorders [17], similar
to our data considering that out of 4 cases of Anxiety Dis-
orders, 1 had co-morbidity with MDD and 2 had comor-
bidity with PD, and only 1 was independent of the mood
disorder. Thus, the total psychiatric cases were 19 (82.6%).
The association with bipolar spectrum disorders was
confirmed using this more inclusive method, i.e. the
MDQ questionnaire, which is capable of including a
wider spectrum of bipolar disorders in the “positives”
compared to the DSM-IV criteria. The reliability of the
diagnosis of Bipolar Disorder using structured tools and
the clinical judgment in a clinic is in fact controversial,
with some researchers viewing them as reliable [32,33]
and others considering them as not reliable [20,34].
Our study shows an association between Bipolar Dis-
order and WD using the strict algorithm of DSM-IV or
using the more comprehensive “spectrum” subject
detected by MDQ.
Our study showed an association between bipolar dis-
orders and lower quality of life as measured using SF-12.
However, the design of the study did not allow us to
clarify whether the bipolarity caused the lower quality of
life or whether this was a confounding factor due to an-
other factor (as cerebral damage) causing both bipolarity
and lower quality of life.
The strong association between bipolar disorders and
WD should be interpreted, keeping in mind the modifi-
cation of the diagnostic criteria and the evolution of the
concept of “Bipolar Spectrum Disorders” in the last few
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past of “schizophrenia-like psychosis” in WD were due
to use of a different definition of schizophrenia com-
pared to current psychiatric diagnostic criteria. In con-
trast, the association of WD and bipolar disorder may
explain the frequent descriptions of “loss of emotional
control, hyperactivity, or loss of sexual inhibition, irrit-
ability” reported in WD patients [4,16]. A high risk of bi-
polar disorders in WD may also be related to the higher
incidence of suicidal behavior, which is present in 4% to
16% of patients with WD across studies [13,36].
Machado and colleagues [16] suggested that there was a
higher association between bipolar disorder and WD than
has been reported in the literature. In their case series,
which describes the neurological manifestations of 119
patients with WD, the authors observed the psychiatric
disorders catatonia, agitation, aggression, delusional
thoughts, and mania. The same group, noting that there
are few reports in the literature of WD patients with typ-
ical bipolar affective disorder [18], described a patient with
WD whose initial manifestation was a manic episode fol-
lowed by depression. Tremors in the upper limbs
appeared one year after the onset of symptoms. The diag-
nosis of WD was established three years after the first
symptoms appeared, based on the neuropsychiatric pic-
ture, detection of Kayser-Fleischer rings, and the results of
diagnostic tests that indicated chronic liver disease and ex-
cess copper. Another case of mania as the first manifest-
ation of WD was described earlier by Kumar Chand et al.
[19] in an 18-year-old boy who presented to a psychiatric
clinic with manic syndrome and a high propensity for
extrapyramidal symptoms due to a neuroleptic. The au-
thor concluded that psychiatrists need to recognize that
WD can rarely present as an isolated psychiatric symp-
tom, including mania. Thus, early and severe extrapyram-
idal symptoms secondary to neuroleptic exposure in an
adolescent warrant a detailed evaluation to rule out under-
lying neuropsychiatric conditions. Our results, which
underline the strong association between bipolar disorder
and WD, support this idea.
It is interesting to consider these results in light of the
pathogenic hypothesis.
Early studies showed that women affected by chronic
depression sometimes have copper, zinc, and cesium de-
ficiencies [37,38]. Later studies suggest that the presence
of depression and other neuropsychiatric symptoms is
due to the deposit of copper in the central nervous sys-
tem [39]. Eggers et al. [40] used SPECT to demonstrate
a reduction in thalamic-hypothalamic presynaptic dopa-
mine and serotonin transporters due to the accumula-
tion of copper. There was a negative correlation between
the density of presynaptic dopamine transporters and
the severity of depression as assessed using the Hamilton
Rating Scale for Depression.It was recently hypothesized that trace elements play
an important role in the pathogenesis of bipolar disor-
ders by causing neurodegeneration [41]. Moreover, es-
sential elements like vanadium have been implicated as
a causative factor for bipolar mood disorder, while ele-
vated vanadium and molybdenum levels have been
reported in serum samples from bipolar mood disorder
patients [41]. This latter study showed, using DSM-IV
standard diagnostic criteria and classification into types
I, II, and V according to the concept of Young and Kler-
man, that Na, K, P, Cu, Al, and Mn were elevated signifi-
cantly in Bipolar I (Mania) (P< 0.001). In Bipolar II
hypomania, Na, S, Al, and Mn were increased signifi-
cantly (P< 0.02), while in Bipolar II depression, Na, K,
Cu, and Al were increased significantly (P< 0.001). Fi-
nally, in Bipolar V, Na, Mg, P, Cu, and Al were increased
significantly (P< 0.002) compared to a control group
[41]. A recent study by Gonzales-Estecha and colleagues
[21] found higher serum copper and zinc, blood lead
and cadmium, and urine lead, cadmium, and thallium
concentrations in patients diagnosed with bipolar disor-
ders compared to a control group.
Increased neuronal oxidative stress (OxS) induces
deleterious effects on signal transduction, structural
plasticity and cellular resilience, mostly by inducing lipid
peroxidation in membranes, proteins and genes [42]. It
has been hypothesized that these pathological processes
occur in critical brain circuits that regulate affective
functioning, emotions, motoric behavior and pleasure
involved in bipolar disorder (BD) [43,44].
The brain is particularly vulnerable to oxidative damage
since it contains large amounts of polysaturated fatty acids
and possesses low antioxidant capacity [45]. Several stud-
ies have demonstrated altered OxS parameters in the
pathophysiology and therapeutics of BD, including
changes in the levels of enzymes superoxide dismutase
(SOD), catalase (CAT) and thiobarbituric acid reactive
substances (TBARS) [46]. The well-known stabilizing
agent Lithium was found to limit the enzyme activity, po-
tentially lowering hydrogen peroxide and hydroxyl radical
formation. Similarly, lithium was also shown to reverse
increased OxS parameters in BD [43,47]. For instance, a
decline in lipid peroxidation and an increase in CAT levels
were observed in valproate and lithium-treated rats
[42,48]. Accumulation of copper was shown to increase
oxidative stress in bivalve species [49]. In skeletal muscle
of Broilers Under Heat Stress, copper decreases because
of dietary Selenium, Vitamin E, and their combination
with an increase in antioxidant defense [50]. In humans
accumulation of copper was associated with oxidative
stress in allergic asthma patients, and introduction of nu-
tritional supplement therapy accompanies improved oxi-
dative stress, immune response, pulmonary function, and
decrease in copper plasma levels [51]. On the other hands
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generative disease such as Niemann-Pick C [52]. Interest-
ingly, Nieman-Pick C disease was specifically indicated to
be associated with Bipolar Disorders [53]. If the results of
our study are further confirmed, it will lend significant
support to the hypothesis that minerals such as copper
play an etiological role in psychiatric disorders, and WD
may serve as a pathogenic model for the bipolar disorder.Limitations
This study was limited by its small sample size. Further
research is warranted to confirm the results and the role
that neurological lesions play in the pathogenesis of bi-
polar disorders. In addition, the link between neuro-
logical lesions, bipolar disorders, and low level of quality
of life in WD awaits further clarification.
In agreement with the literature [11], this study indi-
cated a high risk for panic disorder (OR= 1.7) and for
anxiety disorders as a whole (OR= 4.5) in WD, although
there was no statistically significant difference between
cases and controls. The finding that WD patients did
not have an increased risk of anxiety disorders must be
interpreted with caution since the power of the study
was insufficient in terms of revealing low-level risk.
In this study, the diagnosis of WD in the cases was
made using standardized tools and clinical and labora-
tories assays. In contrast, the data bank used for extrac-
tion of control data reported a WD diagnosis only on
the basis of the anamnesis of the subject in the ‘general
health’ section of the questionnaire. Thus, there may be
a slight risk of false negatives in the group of controls,
although this risk was very low due to the rarity of WD
in the community (1:30,000; thus the probability of a
control subject not reporting WD would be 30,000/92).
Even if there was a false negative among the control sub-
jects, this would reinforce the null hypothesis of no
increased risk for mood disorders in WD. This limitation
therefore does not invalidate the results of the study.
In general, reliability and validity of diagnosis of Bipo-
lar Disorders using standardized tools (as ANTAS-SCID)
and self-administered questionnaire (as MDQ) [18], may
be problematic, however, this is a general limitation of
the epidemiological research in psychiatry more than a
specific limit of this study. We have tried to address this
limitation, at least partially, by using a clinician for the
interview and a semi-structured tool as opposed to a
medically lay person with rigid and structured interview
and by using both methodologies (interviews and self-
reporting tools).
This study may have inducted a Berskon’s Bias due to
the case control design, on the other hand, the study
was carried out in a general hospital setting without a
psychiatric ward, therefore this risk is relatively low.Conclusions
This study was the first to show an association between
BD and WD using standardized diagnostic tools and a
case control design. Reports in the literature about
increased schizophrenia-like psychosis in WD and a lack
of association with bipolar disorders may thus have been
based on a more inclusive diagnosis of schizophrenia in
the past. Our findings may explain the frequent reports
of loss of emotional control, hyperactivity, loss of sexual
inhibition, and irritability in WD patients.
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